33.15

1.66% -0.56

Pre-market: 33.99 0.84 +2.53%

Veracyte Inc (VCYT)

Overview News Price History Option Chain Financials Discussions Forecast

Veracyte Inc stock is traded at $33.15, with a volume of 807.53K. It is down -1.66% in the last 24 hours and down -1.16% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Previous Close:

$33.71

Open:

$33.75

24h Volume:

807.53K

Relative Volume:

0.90

Market Cap:

$2.63B

Revenue:

$517.15M

Net Income/Loss:

$66.35M

P/E Ratio:

40.37

EPS:

0.8212

Net Cash Flow:

$126.63M

1W Performance:

+0.36%

1M Performance:

-1.16%

6M Performance:

-6.99%

1Y Performance:

+5.36%

1-Day Range:

$31.95

$33.90

1-Week Range:

$31.95

$34.63

52-Week Range:

$22.61

$50.71

Veracyte Inc Stock (VCYT) Company Profile

Name

Veracyte Inc

Sector

Healthcare (1111)

Industry

Diagnostics & Research (52)

Phone

(650) 243-6300

Address

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

755

Twitter

@veracyte

Next Earnings Date

2026-05-05

Latest SEC Filings

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCYT Veracyte Inc	33.15	2.66B	517.15M	66.35M	126.63M	0.8212
TMO Thermo Fisher Scientific Inc	466.70	194.94B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	178.57	137.69B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	560.93	45.19B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.42	34.50B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	311.20	32.91B	3.17B	642.63M	516.49M	10.77

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	Jefferies	Buy
Dec-02-25	Resumed	Morgan Stanley	Underweight
Oct-20-25	Initiated	Canaccord Genuity	Hold
Mar-20-25	Initiated	Craig Hallum	Buy
Dec-05-24	Downgrade	Goldman	Buy → Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-16-24	Initiated	UBS	Buy
Oct-10-24	Initiated	Guggenheim	Buy
Feb-23-24	Reiterated	Needham	Buy
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Nov-18-21	Resumed	Goldman	Buy
Jun-15-21	Initiated	Raymond James	Outperform
Feb-18-21	Resumed	Needham	Buy
Jan-28-21	Initiated	Truist	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-09-20	Initiated	Morgan Stanley	Underweight
Jul-31-19	Initiated	Lake Street	Buy
Jul-02-19	Initiated	Needham	Buy
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Janney	Buy → Neutral
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-31-17	Resumed	BTIG Research	Buy
Nov-14-16	Resumed	Leerink Partners	Outperform
Dec-18-15	Initiated	Cantor Fitzgerald	Buy
Jun-11-15	Reiterated	Leerink Partners	Outperform
Nov-26-13	Initiated	William Blair	Outperform

View All

Veracyte Inc Stock (VCYT) Latest News

02:00 AM

Emerging Sub-Segments Transforming the Thyroid Cancer Diagnostics Market Landscape - openPR.com

02:00 AM

Apr 23, 2026

Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN

Apr 23, 2026

Apr 22, 2026

VCYT Veracyte delivers triple digit Q4 2025 EPS beat and 16 percent annual revenue growth despite mild stock dip.EBITDA Margin - Xã Châu Thành

Apr 22, 2026

Veracyte (NASDAQ: VCYT) asks investors to back directors, auditor and larger equity plan - Stock Titan

Apr 22, 2026

Apr 21, 2026

Emerging Growth Patterns Driving Expansion in the Liquid Biopsy for Cancer Diagnostics Market - openPR.com

Apr 21, 2026

Apr 20, 2026

VCYT Maintained by Canaccord Genuity -- Price Target Lowered to $40 - GuruFocus

Apr 20, 2026

CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $40 - Moomoo

Apr 20, 2026

Veracyte Price Target Cut to $40.00/Share From $43.00 by Canaccord Genuity - Moomoo

Apr 20, 2026

Apr 19, 2026

Is Veracyte (VCYT) Offering Value After Mixed Returns And Conflicting Valuation Signals - Yahoo Finance

Apr 19, 2026

Apr 16, 2026

Assessing Veracyte (VCYT) Valuation After A Recent Share Price Rebound - Sahm

Apr 16, 2026

Sumitomo Mitsui Trust Group Inc. Sells 224,185 Shares of Veracyte, Inc. $VCYT - MarketBeat

Apr 16, 2026

Apr 15, 2026

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 - BioSpace

Apr 15, 2026

Apr 14, 2026

Veracyte to Release Q1 2026 Results on May 5 - National Today

Apr 14, 2026

Veracyte to Release Q1 2026 Earnings on May 5 - National Today

Apr 14, 2026

Veracyte (NASDAQ: VCYT) awards 44,221 RSUs to Chief Dev and Tech Officer - Stock Titan

Apr 14, 2026

Jefferies Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $45 - 富途牛牛

Apr 14, 2026

Veracyte (NASDAQ:VCYT) Coverage Initiated at Jefferies Financial Group - MarketBeat

Apr 13, 2026

Jefferies Initiates Veracyte at Buy With $45 Price Target - marketscreener.com

Apr 13, 2026

Jefferies initiates Veracyte stock with buy on diagnostics growth - Investing.com UK

Apr 13, 2026

Jefferies initiates Veracyte stock with buy on diagnostics growth By Investing.com - Investing.com Canada

Apr 13, 2026

Apr 12, 2026

Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Wygant Jonathan - Moomoo

Apr 12, 2026

Apr 11, 2026

VCYT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 11, 2026

Apr 10, 2026

Sentiment Watch: Can Veracyte Inc be the next market leaderPortfolio Gains Report & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026